Jazz Pharmaceuticals gets US FDA approval of Xywav for cataplexy associated with narcolepsy

This article was originally published here

Xywav is an oxybate product with a unique composition of cations resulting in 92 percent less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate

The post Jazz Pharmaceuticals gets US FDA approval of Xywav for cataplexy associated with narcolepsy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply